局部SAHA与吡非尼酮改善犬角膜基质损伤后光学透明度的离体研究
该离体犬角膜模型研究评估局部SAHA和吡非尼酮对基质损伤后角膜雾状混浊的影响。结果显示两种药物组雾状混浊像素强度差及雾状面积均显著低于对照组(P<0.01),但上皮化时间无显著差异(P=0.368)。
要点
- SAHA和吡非尼酮组21天时光学透明度优于安慰剂组,雾状混浊显著减轻。
- 三组上皮化时间无显著差异(对照组47.25h,SAHA组45.00h,吡非尼酮组43.50h;P=0.368)。
- 角膜轮廓与雾状混浊的地理分布相关。
核心结论
- 基质损伤的离体犬角膜经SAHA或吡非尼酮治疗21天后光学透明度优于安慰剂组。
- 各组间上皮化速率无显著差异。
- 角膜轮廓与雾状混浊的地理分布相关。
研究设计与样本
- 对照组8只安慰剂处理,SAHA组8只每6小时局部给药,吡非尼酮组8只每6小时局部给药。
主要发现
- 上皮化平均时间:对照组47.25小时,SAHA组45.00小时,吡非尼酮组43.50小时,组间无显著差异(P=0.368)。
- 雾状区与非雾状区像素强度中位差值:对照组21.5,SAHA组8.0,吡非尼酮组8.0,组间显著(P<0.01)。
- 雾状面积中位数:对照组12.96 mm2,SAHA组5.70 mm2,吡非尼酮组5.92 mm2,组间显著(P<0.01)。
关键数值与推荐
- 每6小时局部应用SAHA或吡非尼酮,每6小时荧光素染色拍照评估上皮化速率,每周拍照评估光学透明度(雾状混浊)。
- 通过分析损伤区(雾状)与非损伤区(非雾状)像素强度差异及雾状表面积进行定量。
临床怎么用
- 离体犬角膜模型提示SAHA和吡非尼酮可能减轻基质损伤后角膜雾状混浊,但需进一步在体研究验证。
- 两种药物未显著改变上皮化速率,提示其改善透明度可能不依赖于上皮愈合速度。
局限性
- 研究为离体犬角膜模型,结果不能直接外推至在体人类角膜。
- 样本量较小(每组8只),观察期为21天,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effect of topical suberanilohydroxamic acid (SAHA) and 5-methyl-1-phenyl-2[1H]-pyridone (pirfenidone) on the degree of corneal haze in the stromal wounded ex vivo canine cornea. METHODS: Twenty-four corneoscleral rims from normal dogs were uniformly wounded with an excimer laser and placed into culture medium with an air-liquid interface. The control group (n = 8) contained placebo-treated corneas. Treatment group 1 (n = 8) received SAHA topically every 6 hours. Treatment group 2 (n = 8) received pirfenidone topically every 6 hours. Each cornea was fluorescein stained and macrophotographed every 6 hours to assess epithelialization rate. All corneas were also macrophotographed weekly to assess optical clarity (haze). Images were analyzed for differences in pixel intensity between wounded (haze) and unwounded (nonhaze) regions, and haze surface area for each cornea was calculated. RESULTS: The mean epithelialization time was 47.25 hours in the control group, 45.00 hours in the SAHA group, and 43.50 hours in the pirfenidone group, revealing no significant difference (P = 0.368). The median difference in pixel intensity between haze and nonhaze areas was 21.5 in the control group, 8.0 in the SAHA group, and 8.0 in the pirfenidone group, which is significant (P < 0.01). The median haze surface area was 12.96 mm2 in the control group, 5.70 mm2 in the SAHA group, and 5.92 mm2 in the pirfenidone group, which is significant (P < 0.01). CONCLUSIONS: Stromal-wounded ex vivo canine corneas exhibited greater optical clarity when treated with SAHA and pirfenidone than when placebo treated at 21 days. There was no significant difference in epithelialization rate between groups. Corneal contour was correlated with geographic haze distribution.
引用
- Berkowski WM, Gibson DJ, Seo S, et al. Assessment of Topical Therapies for Improving the Optical Clarity Following Stromal Wounding in a Novel Ex Vivo Canine Cornea Model. Invest Ophthalmol Vis Sci. 2018. PMID: 30658034. doi:10.1167/iovs.17-23085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。